Granted Patent
B2
US 12,521,400 · App. 18/782,646 · Granted Jan 13, 2026
Administration of benzodiazepine compositions
Inventors:
Steve Cartt (Hillsborough, CA); David Medeiros (Sparks, NV); Garry Thomas Gwozdz (Jim Thorpe, PA); Andrew Loxley (Brussels, BE); Mark Mitchnick (East Hampton, NY)
Assignee:
Neurelis, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
Claims (24)
1 . A pharmaceutical composition for intranasal administration comprising:
about 1 to about 20 mg of diazepam dissolved in about 45% to about 85% (w/w) of one or more natural or synthetic tocopherols or tocotrienols selected from the group consisting of α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, α-tocotrienol, β-tocotrienol, γ-tocotrienol, δ-tocotrienol, tocophersolan, any esters thereof and any combinations thereof, and about 25% to about 40% (w/w) of one or more alcohols selected from the group consisting of ethanol, propyl alcohol, butyl alcohol, pentanol, benzyl alcohol, and any combinations thereof, wherein the pharmaceutical composition is a solution of 50 μL to 150 μL, and wherein the pharmaceutical composition is in a pharmaceutically-acceptable spray formulation for intranasal administration.
2 . The pharmaceutical composition of claim 1 , wherein the natural or synthetic tocopherols or tocotrienols are selected from the group consisting of: α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, tocophersolan, any esters thereof and any combinations thereof.
3 . The pharmaceutical composition of claim 1 , wherein the natural or synthetic tocopherols or tocotrienols is α-tocopherol.
4 . The pharmaceutical composition of claim 1 , wherein the one or more alcohols is selected from the group consisting of ethanol, propyl alcohol, butyl alcohol, pentanol, benzyl alcohol, isomers thereof and any combinations thereof.
5 . The pharmaceutical composition of claim 1 , wherein the diazepam is present in the pharmaceutical solution at a concentration of about 10 mg/mL to about 250 mg/mL.
6 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical solution comprises one or more natural or synthetic tocopherols or tocotrienols, or any combinations thereof in an amount from about 60% to about 75% (w/w).
7 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises at least one additional ingredient selected from the group consisting of stabilizers, coloring agents, pH adjusters, buffering agents, preservatives, wetting agents, flavoring agents and combinations thereof.
8 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises an absorption enhancer.
9 . The pharmaceutical composition of claim 8 , wherein the absorption enhancer is present in the pharmaceutical composition at a concentration of up to 20% (w/v).
10 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is about 100 μL.
11 . The pharmaceutical composition of claim 1 , wherein the therapeutically effective amount of the diazepam is about 2 mg to about 10 mg.
12 . A pharmaceutical composition for intranasal administration comprising:
about 1 to about 20 mg of diazepam dissolved in about 45% to about 85% (w/w) of α-tocopherol, and about 25% to about 40% (w/w) of one or more alcohols selected from the group consisting of ethanol, propyl alcohol, butyl alcohol, pentanol, benzyl alcohol, isomers thereof and any combinations thereof, wherein the pharmaceutical composition is a solution of 50 μL to 150 μL, and wherein the pharmaceutical composition is in a pharmaceutically-acceptable spray formulation for intranasal administration.
13 . The pharmaceutical composition of claim 12 , wherein the diazepam is present in the pharmaceutical solution at a concentration of about 10 mg/mL to about 250 mg/mL.
14 . The pharmaceutical composition of claim 12 , wherein the diazepam is about 2 mg to about 10 mg.
15 . The pharmaceutical composition of claim 12 , wherein the pharmaceutical solution comprises α-tocopherol in an amount from about 60% to about 75% (w/w).
16 . The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition further comprises at least one additional ingredient selected from the group consisting of stabilizers, coloring agents, pH adjusters, buffering agents, preservatives, wetting agents, flavoring agents and combinations thereof.
17 . The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition further comprises an absorption enhancer.
18 . The pharmaceutical composition of claim 17 , wherein the absorption enhancer is present in the pharmaceutical composition at a concentration of up to 20% (w/v).
19 . The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition is about 100 μL.
20 . A pharmaceutical composition for intranasal administration comprising:
about 1 to about 20 mg of diazepam dissolved in about 45% to about 85% (w/w) of α-tocopherol and about 25% to about 40% (w/w) of one or more alcohols selected from the group consisting of ethanol, propyl alcohol, butyl alcohol, pentanol, benzyl alcohol, and any combinations thereof, wherein the pharmaceutical composition is a solution of about 100 μL, and wherein the pharmaceutical composition is in a pharmaceutically-acceptable spray formulation for intranasal administration.
21 . The pharmaceutical composition of claim 20 , wherein the pharmaceutical composition further comprises an absorption enhancer.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 24, 2024
From: CARTT, STEVE; MEDEIROS, DAVID; GWOZDZ, GARRY THOMAS; LOXLEY, ANDREW; MITCHNICK, MARK; HALE, DAVID F.; MAGGIO, EDWARD T.
To: HALE BIOPHARMA VENTURES, LLC
Reel/Frame 068072/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 24, 2024
From: HALE BIOPHARMA VENTURES, LLC
To: NEURELIS, INC.
Reel/Frame 068072/0444 →
Continuity (6)
Provisional Application
61040558
· Mar 28, 2008
References Cited (400)
US 3102116A
· Chase
· 1963
[cited by applicant]
US 3109843A
· Reeder et al.
· 1963
[cited by applicant]
US 3136815A
· Reeder et al.
· 1964
[cited by applicant]
US 3243427A
· Reeder et al.
· 1966
[cited by applicant]
US 3296249A
· Bell
· 1967
[cited by applicant]
US 3299053A
· Archer et al.
· 1967
[cited by applicant]
US 3340253A
· Reeder et al.
· 1967
[cited by applicant]
US 3371085A
· Reeder et al.
· 1968
[cited by applicant]
US 3374225A
· Reeder et al.
· 1968
[cited by applicant]
US 3547828A
· Mansfield et al.
· 1970
[cited by applicant]
US 3567710A
· Fryer et al.
· 1971
[cited by applicant]
US 3609145A
· Moffett
· 1971
[cited by applicant]
US 3722371A
· Boyle
· 1973
[cited by applicant]
US 3849341A
· Lamberti et al.
· 1974
[cited by applicant]
US 3949072A
· Tenta
· 1976
[cited by applicant]
US 3987052A
· Hester, Jr.
· 1976
[cited by applicant]
US 4130709A
· Nagarajan
· 1978
[cited by applicant]
US 4280957A
· Walser et al.
· 1981
[cited by applicant]
US 4397951A
· Taki et al.
· 1983
[cited by applicant]
US 4440675A
· Braude
· 1984
[cited by applicant]
US 4608278A
· Frank et al.
· 1986
[cited by applicant]
US 4657901A
· Ueda et al.
· 1987
[cited by applicant]
US 4690952A
· Kagatani et al.
· 1987
[cited by applicant]
US 4748158A
· Biermann et al.
· 1988
[cited by applicant]
US 4826689A
· Violanto
· 1989
[cited by applicant]
US 4868289A
· Magnusson et al.
· 1989
[cited by applicant]
US 4921838A
· Catsimpoolas et al.
· 1990
[cited by applicant]
US 4973465A
· Baurain et al.
· 1990
[cited by applicant]
US 4997454A
· Molante et al.
· 1991
[cited by applicant]
US 5091188A
· Haynes
· 1992
[cited by applicant]
US 5100591A
· Leclef et al.
· 1992
[cited by applicant]
US 5118528A
· Fessi et al.
· 1992
[cited by applicant]
US 5122187A
· Schwarz et al.
· 1992
[cited by applicant]
US 5145684A
· Liversidge et al.
· 1992
[cited by applicant]
US 5182258A
· Chiou
· 1993
[cited by applicant]
US 5188837A
· Domb
· 1993
[cited by applicant]
US 5192528A
· Radhakrishnan et al.
· 1993
[cited by applicant]
US 5198420A
· Donahoe et al.
· 1993
[cited by applicant]
US 5236707A
· Stewart, II
· 1993
[cited by applicant]
US 5268461A
· Shoji et al.
· 1993
[cited by applicant]
US 5308531A
· Urfer et al.
· 1994
[cited by applicant]
US 5317010A
· Pang et al.
· 1994
[cited by applicant]
US 5369095A
· Kee et al.
· 1994
[cited by applicant]
US 5457100A
· Daniel
· 1995
[cited by applicant]
US 5550220A
· Meyer et al.
· 1996
[cited by applicant]
US 5556757A
· Alstyne et al.
· 1996
[cited by applicant]
US 5556940A
· Willick et al.
· 1996
[cited by applicant]
US 5560932A
· Bagchi et al.
· 1996
[cited by applicant]
US 5639733A
· Koike et al.
· 1997
[cited by applicant]
US 5661130A
· Meezan et al.
· 1997
[cited by applicant]
US 5662883A
· Bagchi et al.
· 1997
[cited by applicant]
US 5665331A
· Bagchi et al.
· 1997
[cited by applicant]
US 5716642A
· Bagchi et al.
· 1998
[cited by applicant]
US 5738845A
· Imakawa
· 1998
[cited by applicant]
US 5780062A
· Frank et al.
· 1998
[cited by applicant]
US 5789375A
· Mukae et al.
· 1998
[cited by applicant]
US 5795896A
· Lofroth et al.
· 1998
[cited by applicant]
US 5814607A
· Patton
· 1998
[cited by applicant]
US 5817634A
· Meezan et al.
· 1998
[cited by applicant]
US 5831089A
· Huber
· 1998
[cited by applicant]
US 5861510A
· Piscopio et al.
· 1999
[cited by applicant]
US 5863949A
· Robinson et al.
· 1999
[cited by applicant]
US 5955425A
· Morley et al.
· 1999
[cited by applicant]
US 5981719A
· Woiszwillo et al.
· 1999
[cited by applicant]
US 6004574A
· Backstrom et al.
· 1999
[cited by applicant]
US 6090925A
· Woiszwillo et al.
· 2000
[cited by applicant]
US 6143211A
· Mathiowitz et al.
· 2000
[cited by applicant]
US 6165484A
· Raad et al.
· 2000
[cited by applicant]
US 6193985B1
· Sonne
· 2001
[cited by applicant]
US 6235224B1
· Mathiowitz et al.
· 2001
[cited by applicant]
US 6254854B1
· Edwards et al.
· 2001
[cited by applicant]
US 6268053B1
· Woiszwillo et al.
· 2001
[cited by applicant]
US 6316029B1
· Jain et al.
· 2001
[cited by applicant]
US 6316410B1
· Barbier et al.
· 2001
[cited by applicant]
US 6375986B1
· Ryde et al.
· 2002
[cited by applicant]
US 6395300B1
· Straub et al.
· 2002
[cited by applicant]
US 6428814B1
· Bosch et al.
· 2002
[cited by applicant]
US 6458387B1
· Scott et al.
· 2002
[cited by applicant]
US 6461591B1
· Keller et al.
· 2002
[cited by applicant]
US 6482516B1
· Sadek et al.
· 2002
[cited by applicant]
US 6482834B2
· Spada et al.
· 2002
[cited by applicant]
US 6495498B2
· Niemiec et al.
· 2002
[cited by applicant]
US 6524557B1
· Backstrom et al.
· 2003
[cited by applicant]
US 6551578B2
· Adjei et al.
· 2003
[cited by applicant]
US 6583616B1
· Bomya
· 2003
[cited by applicant]
US 6607784B2
· Kipp et al.
· 2003
[cited by applicant]
US 6608073B1
· Hussain et al.
· 2003
[cited by applicant]
US 6610271B2
· Wermeling
· 2003
[cited by applicant]
US 6616914B2
· Ward et al.
· 2003
[cited by applicant]
US 6627211B1
· Choi et al.
· 2003
[cited by applicant]
US 6794357B1
· Backstrom et al.
· 2004
[cited by applicant]
US 6855332B2
· Gizurarson et al.
· 2005
[cited by applicant]
US 6869617B2
· Kipp et al.
· 2005
[cited by applicant]
US 6884436B2
· Kipp et al.
· 2005
[cited by applicant]
US 6908626B2
· Cooper et al.
· 2005
[cited by applicant]
US 6932962B1
· Backstrom et al.
· 2005
[cited by applicant]
US 6991785B2
· Frey, II
· 2006
[cited by applicant]
US 7008920B2
· Kimura et al.
· 2006
[cited by applicant]
US 7037528B2
· Kipp et al.
· 2006
[cited by applicant]
US 7132112B2
· Choi et al.
· 2006
[cited by applicant]
US 7220402B1
· Andersen et al.
· 2007
[cited by applicant]
US 7425542B2
· Maggio
· 2008
[cited by applicant]
US 7434579B2
· Young et al.
· 2008
[cited by applicant]
US 7524510B2
· Arnold et al.
· 2009
[cited by applicant]
US 8530463B2
· Cartt et al.
· 2013
[cited by applicant]
US 8895546B2
· Cartt et al.
· 2014
[cited by applicant]
US 8927497B2
· Maggio
· 2015
[cited by applicant]
US 9192570B2
· Wyse et al.
· 2015
[cited by applicant]
US 9642913B2
· Maggio
· 2017
[cited by applicant]
US 9763876B2
· Cartt et al.
· 2017
[cited by applicant]
US 20010042932A1
· Mathiowitz et al.
· 2001
[cited by applicant]
US 20020110524A1
· Cowan et al.
· 2002
[cited by applicant]
US 20020127278A1
· Kipp et al.
· 2002
[cited by applicant]
US 20020141971A1
· Frey, II
· 2002
[cited by applicant]
US 20020168402A1
· Kipp et al.
· 2002
[cited by applicant]
US 20030017203A1
· Crotts et al.
· 2003
[cited by applicant]
US 20030031719A1
· Kipp et al.
· 2003
[cited by applicant]
US 20030040497A1
· Teng et al.
· 2003
[cited by applicant]
US 20030087820A1
· Young et al.
· 2003
[cited by applicant]
US 20030095928A1
· McGurk et al.
· 2003
[cited by applicant]
US 20030100755A1
· Sham et al.
· 2003
[cited by applicant]
US 20030118547A1
· Vandenberg
· 2003
[cited by applicant]
US 20030118594A1
· Nag et al.
· 2003
[cited by applicant]
US 20030158206A1
· Billotte et al.
· 2003
[cited by applicant]
US 20030170206A1
· Rasmussen et al.
· 2003
[cited by applicant]
US 20030170752A1
· Andersen et al.
· 2003
[cited by applicant]
US 20030181411A1
· Bosch et al.
· 2003
[cited by applicant]
US 20040101482A1
· Sanders
· 2004
[cited by applicant]
US 20040115135A1
· Quay
· 2004
[cited by applicant]
US 20040126358A1
· Warne et al.
· 2004
[cited by applicant]
US 20040141923A1
· Dugger, III et al.
· 2004
[cited by applicant]
US 20040147473A1
· Warrell, Jr.
· 2004
[cited by applicant]
US 20040176359A1
· Wermeling
· 2004
[cited by applicant]
US 20040209814A1
· Nauck et al.
· 2004
[cited by applicant]
US 20040248846A1
· Quay et al.
· 2004
[cited by applicant]
US 20040258663A1
· Quay et al.
· 2004
[cited by applicant]
US 20050130260A1
· Linden et al.
· 2005
[cited by applicant]
US 20050153956A1
· Merkus
· 2005
[cited by applicant]
US 20050215475A1
· Ong et al.
· 2005
[cited by applicant]
US 20050234101A1
· Stenkamp et al.
· 2005
[cited by applicant]
US 20050276843A1
· Quay et al.
· 2005
[cited by applicant]
US 20060045868A1
· Meezan et al.
· 2006
[cited by applicant]
US 20060045869A1
· Meezan et al.
· 2006
[cited by applicant]
US 20060046962A1
· Meezan et al.
· 2006
[cited by applicant]
US 20060046969A1
· Maggio
· 2006
[cited by applicant]
US 20060074025A1
· Quay et al.
· 2006
[cited by applicant]
US 20060106227A1
· Reddy et al.
· 2006
[cited by applicant]
US 20060147386A1
· Wermeling
· 2006
[cited by applicant]
US 20060178290A1
· Bara
· 2006
[cited by applicant]
US 20060183674A1
· Brand et al.
· 2006
[cited by applicant]
US 20060198896A1
· Liversidge et al.
· 2006
[cited by applicant]
US 20060222597A1
· Dugger
· 2006
[cited by applicant]
US 20070059254A1
· Singh
· 2007
[cited by applicant]
US 20070098805A1
· Liversidge
· 2007
[cited by applicant]
US 20070111938A1
· Pert et al.
· 2007
[cited by applicant]
US 20070298010A1
· Maggio
· 2007
[cited by applicant]
US 20080070904A1
· Jamieson et al.
· 2008
[cited by applicant]
US 20080076761A1
· Jamieson et al.
· 2008
[cited by applicant]
US 20080194461A1
· Maggio
· 2008
[cited by applicant]
US 20080200418A1
· Maggio
· 2008
[cited by applicant]
US 20080248123A1
· Swanson et al.
· 2008
[cited by applicant]
US 20080268032A1
· Maggio
· 2008
[cited by applicant]
US 20080275030A1
· Gizurarson et al.
· 2008
[cited by applicant]
US 20080279784A1
· Cartt et al.
· 2008
[cited by applicant]
US 20080299079A1
· Meezan et al.
· 2008
[cited by applicant]
US 20090004281A1
· Nghiem et al.
· 2009
[cited by applicant]
US 20090047234A1
· Touitou et al.
· 2009
[cited by applicant]
US 20090047347A1
· Maggio
· 2009
[cited by applicant]
US 20090130216A1
· Cartt et al.
· 2009
[cited by applicant]
US 20090156478A1
· Lau et al.
· 2009
[cited by applicant]
US 20090163447A1
· Maggio
· 2009
[cited by applicant]
US 20090258865A1
· Cartt et al.
· 2009
[cited by applicant]
US 20090297619A1
· Swanson et al.
· 2009
[cited by applicant]
US 20090304801A1
· Liversidge et al.
· 2009
[cited by applicant]
US 20090326193A1
· Maggio et al.
· 2009
[cited by applicant]
US 20100034880A1
· Sintov
· 2010
[cited by examiner]
US 20100068209A1
· Maggio
· 2010
[cited by applicant]
US 20100112050A1
· Ryoo et al.
· 2010
[cited by applicant]
US 20100160378A1
· Maggio
· 2010
[cited by applicant]
US 20100203014A1
· Maggio
· 2010
[cited by applicant]
US 20100203119A1
· Leane et al.
· 2010
[cited by applicant]
US 20100209485A1
· Maggio
· 2010
[cited by applicant]
US 20110038899A1
· Gwozdz et al.
· 2011
[cited by applicant]
US 20110172211A1
· Baek et al.
· 2011
[cited by applicant]
US 20110257096A1
· Maggio
· 2011
[cited by applicant]
US 20120196941A1
· Maggio
· 2012
[cited by applicant]
US 20130065886A1
· Cartt et al.
· 2013
[cited by applicant]
US 20130224300A1
· Maggio
· 2013
[cited by applicant]
US 20130253009A1
· Maggio
· 2013
[cited by applicant]
US 20140128479A1
· Maggio
· 2014
[cited by applicant]
US 20140170220A1
· Cartt et al.
· 2014
[cited by applicant]
US 20150065491A1
· Cartt et al.
· 2015
[cited by applicant]
US 20160199296A1
· Bergenhem et al.
· 2016
[cited by applicant]
US 20170196884A1
· Cartt et al.
· 2017
[cited by applicant]
US 20180235929A1
· Cartt et al.
· 2018
[cited by applicant]
US 20200038320A1
· Cartt et al.
· 2020
[cited by applicant]
US 20230104144A1
· Cartt
· 2023
[cited by examiner]
US 20250281394A1
· Cartt et al.
· 2025
[cited by applicant]
CN 1303674A
· 2001
[cited by applicant]
EP 0396777A1
· 1990
[cited by applicant]
EP 0606046A1
· 1994
[cited by applicant]
EP 0780386A1
· 1997
[cited by applicant]
EP 0818442A2
· 1998
[cited by applicant]
EP 0931788A2
· 1999
[cited by applicant]
EP 0945485A1
· 1999
[cited by applicant]
EP 1004578A2
· 2000
[cited by applicant]
EP 1208863A2
· 2002
[cited by applicant]
EP 1417972A1
· 2004
[cited by applicant]
JP S60208911A
· 1985
[cited by applicant]
JP S61267528A
· 1986
[cited by applicant]
JP H01151528A
· 1989
[cited by applicant]
JP H05507085A
· 1993
[cited by applicant]
JP H0583918B2
· 1993
[cited by applicant]
JP 2003505403A
· 2003
[cited by applicant]
JP 2005508939A
· 2005
[cited by applicant]
JP 2007510722A
· 2007
[cited by applicant]
JP 2009515895A
· 2009
[cited by applicant]
JP 2011516425A
· 2011
[cited by applicant]
JP 6883918B2
· 2021
[cited by applicant]
WO 1990005719A1
· 1990
[cited by applicant]
WO 1991019481A1
· 1991
[cited by applicant]
WO 1994005262A1
· 1994
[cited by applicant]
WO 1995000151A1
· 1995
[cited by applicant]
WO 1995031217A1
· 1995
[cited by applicant]
WO 1996027583A1
· 1996
[cited by applicant]
WO 1996033172A1
· 1996
[cited by applicant]
WO 1997014407A1
· 1997
[cited by applicant]
WO 1998003516A1
· 1998
[cited by applicant]
WO 1998007697A1
· 1998
[cited by applicant]
WO 1998030566A1
· 1998
[cited by applicant]
WO 1998033768A1
· 1998
[cited by applicant]
WO 1998034915A1
· 1998
[cited by applicant]
WO 1998034918A1
· 1998
[cited by applicant]
WO 1999007675A1
· 1999
[cited by applicant]
WO 1999029667A1
· 1999
[cited by applicant]
WO 1999052889A1
· 1999
[cited by applicant]
WO 1999052910A1
· 1999
[cited by applicant]
WO 2000001390A1
· 2000
[cited by applicant]
WO 2000074681A1
· 2000
[cited by applicant]
WO 2003004015A1
· 2003
[cited by applicant]
WO 2003007978A1
· 2003
[cited by applicant]
WO 2003055464A1
· 2003
[cited by applicant]
WO 2005018565A2
· 2005
[cited by applicant]
WO 2005044234A2
· 2005
[cited by applicant]
WO 2005089768A1
· 2005
[cited by applicant]
WO 2005117830A1
· 2005
[cited by applicant]
WO 2006025882A2
· 2006
[cited by applicant]
WO 2006051110A2
· 2006
[cited by applicant]
WO 2006055603A2
· 2006
[cited by applicant]
WO 2006075123A1
· 2006
[cited by applicant]
WO 2006088894A2
· 2006
[cited by applicant]
WO 2007043057A2
· 2007
[cited by applicant]
WO 2007144081A2
· 2007
[cited by applicant]
WO 2008027395A2
· 2008
[cited by applicant]
WO 2008120207A2
· 2008
[cited by applicant]
WO 2008137960A1
· 2008
[cited by applicant]
WO 2009120933A2
· 2009
[cited by applicant]
WO 2009121039A2
· 2009
[cited by applicant]
WO 2012174058A1
· 2012
[cited by applicant]
WO 2012174158A2
· 2012
[cited by applicant]
US 5,849,884 A, 12/1998, Woiszwillo et al. (withdrawn)
[cited by applicant]
Li et al. (International Journal of Pharmaceutics 199 (2000):65-76.) (Year: 2000).
[cited by examiner]
Costantino et al. “Intranasal Delivery: Physicochemical and Therapeutic Aspects” 2007, International J. Pharmaceutics 337:1-24, [filed as EX1118 in IPR2019-00451].
[cited by applicant]
Dale et al. “Intranasal Midazolam: a Comparison of Two Delivery Devices in Human Volunteers” 2006, J . Pharmacy and Pharmacology 58:1311-1318, [filed as EX1128 in IPR2019-00451].
[cited by applicant]
Daniel P. Wermeling Deposition Transcript, Feb. 26, 2020, 150 Pages, [filed as EX2031 in IPR2019-00451].
[cited by applicant]
Davis “Delivery Of Peptide and Non-Peptide Drugs through the Respiratory Tract” Nov. 1999, Pharmaceutical Science & Technology Today 2(11):450-456, [filed as EX1035 in IPR2019-00451, IPR2019-00450, IPR2019-00449].
[cited by applicant]
Davis et al. “Absorption Enhancers for Nasal Drug Delivery” 2003, Clinical Pharmacokinetics 42(13):1107-1128.
[cited by applicant]
Davis et al. “Bioavailability and Pharmacokinetics of Intranasal Hydromorphone in Patients Experiencing Vasomotor Rhinitis” 2004, Clin. Drug Invest. 24(11):633-639, [Filed as EX1120 in IPR2019-00451].
[cited by applicant]
Davis et al. “Effect of Fluticasone Propionate Nasal Spray on Bioavailability of Intranasal Hydromorphone Hydrochloride in Patients With Allergic Rhinitis” 2004, Pharmacotherapy 24(1)26-32, [Filed as EX1119 in IPR2019-0…
[cited by applicant]
De Vry et al. “Effects of Selected Serotonin 5-HT(1) and 5-HT(2) Receptor Agonists on Feeding Behavior: Possible Mechanisms of Action” 2000, Neuroscience and Biobehavioral Reviews 24(3):341-353.
[cited by applicant]
Decision Denying Institution of Inter Partes Review of U.S. Pat. No. 9,763,876, filed Aug. 1, 2019 in IPR2019-00449, 27 Pages.
[cited by applicant]
Decision Denying Institution of Inter Partes Review of U.S. Pat. No. 9,763,876, filed Aug. 1, 2019 in IPR2019-00450, 23 Pages.
[cited by applicant]
Decision Denying Patent Owner's Request on Rehearing of Decision on Institution of U.S. Pat. No. 9,763,876, filed Sep. 27, 2019 in IPR2019-00451, 7 Pages.
[cited by applicant]
Decision Denying Petitioner's Request for Rehearing of Decision Denying Institution of Inter Partes Review of U.S. Pat. No. 9,763,876, filed Sep. 27, 2019 in IPR2019-00449, 8 Pages.
[cited by applicant]
Decision Instituting Inter Partes Review of U.S. Pat. No. 9,763,876, filed Aug. 13, 2019 in IPR2019-00451, 42 Pages.
[cited by applicant]
Declaration of Daniel P. Wermeling, Pharm.D., Executed Jan. 27, 2020, [filed as EX1150 in IPR2019-00451], 175 Pages.
[cited by applicant]
Declaration of Dr. Nicholas A. Peppas, Executed Dec. 6, 2018, [filed as EX1041 in IPR2019-00449], 420 Pages.
[cited by applicant]
Declaration of Dr. Nicholas A. Peppas, Executed Dec. 6, 2018, [filed as EX1041 in IPR2019-00450], 459 Pages.
[cited by applicant]
Declaration of Dr. Nicholas A. Peppas, Executed Dec. 6, 2018, [filed as EX1041 in IPR2019-00451], 459 Pages.
[cited by applicant]
Declaration of Dr. Sveinbjorn Gizurarson, Ph.D., Executed Nov. 4, 2019, [filed as EX2012 in IPR2019-00451], 113 Pages.
[cited by applicant]
Declaration of Michael I. Chakansky Executed Feb. 19, 2020, [filed as EX1152 in IPR2019-00451], 7 Pages.
[cited by applicant]
“Definition of Encephalin” retrieved from the internet: http://medical- dictionary.thefreedictionary.com/p/encephalin (Sep. 13, 2012) 1 Page.
[cited by applicant]
“Definition of Pilus” Merriam-Webster Medical Dictionary, retrieved from the internet: http://www.merriam-webster.com/medical/pilus (May 28, 2013).
[cited by applicant]
“Definition of Villus” Merriam-Webster Medical Dictionary, retrieved from the URL: http://www.merriam-webster.com/medical/villus (May 28, 2013) 2 Pages.
[cited by applicant]
Deshmukh et al. “Lorazepam in the Treatment of Refractory Neonatal Seizures” Oct. 1986, The American J. Diseases of Children 140(10):1042-1044, [filed as EX1036 in IPR2019-00451, IPR2019-00450, IPR2019-00449].
[cited by applicant]
Diastat Label, 2005, [filed as EX2017 in IPR2019-00451], 2 Pages.
[cited by applicant]
Dr. Nicholas Peppas Deposition Transcript, Oct. 24, 2019, 158 Pages, [filed as EX2011 in IPR2019-00451].
[cited by applicant]
Drewe et al. “Enteral Absorption of Octreotide: Absorption Enhancement by Polyoxyethylene-24-cholesterol Ether” 1993, British J. Pharmacology 108(2):298-303.
[cited by applicant]
Drug Prices from Internet, Accessed Jan. 24, 2020, 6 Pages, [filed as EX1081 in IPR2019-00451].
[cited by applicant]
Duquesnoy et al. “Comparative Clinical Pharmacokinetics of Single Doses of Sumatriptan Following Subcutaneous, Oral, Rectal and Intranasal Administration” 1998, European J. Pharmaceutical Sciences 6(2):99-104.
[cited by applicant]
Edman et al. “(D) Routes of Delivery: Case Studies—(1) Nasal Delivery of Peptide Drugs” 1992, Advanced Drug Delivery Reviews 8:165-177, [filed as EX1034 in IPR2019-00451, IPR2019-00450, IPR2019-00449].
[cited by applicant]
Edman et al. “Microspheres as a Nasal Delivery System for Peptide Drugs” 1992, J. Controlled Release, 21 (1992):165-172 [filed as EX1032 in IPR2019-00451, IPR2019-00450, IPR2019-00449].
[cited by applicant]
Eley et al. “In Vitro Assessment of Alkylglycosides as Permeability Enhancers” 2001, AAPS PharmSciTech, 2(3):1-7.
[cited by applicant]
Email Sent Sep. 30, 2019 Requesting Precedential Opinion Panel Review, [filed as EX3001 in IPR2019-00451], 3 Pages.
[cited by applicant]
Epilepsy Fast Facts, Center for Disease Control and Preventions, CDC 24/7, Saving Lives, Protection People, Apr. 9, 2019, pp. 1-2, [filed as EX2001 in IPR2019-00451, IPR2019-00450, PR2019-00449], Retrieved from URL: htt…
[cited by applicant]
Eriksson et al. “Pharmacologic Management of Convulsive Status Epilepticus in Childhood” 2005, Expert Rev Neurotherapeutics 5(6):777-783, [Filed as EX1109 in IPR2019-00451].
[cited by applicant]
European Communication Pursuant to Article 94(3) EPC for European Application No. 12801372.9, mailed Jul. 5, 2016, 7 pages.
[cited by applicant]
European Office Action for European Application No. 08747813.7 mailed Jun. 24, 2011, 5 Pages.
[cited by applicant]
European Office Action for European Application No. 18171484.1 mailed Apr. 6, 2020, 8 Pages.
[cited by applicant]
European Office Action for European Application No. 18171484.1, mailed May 17, 2021, 7 Pages.
[cited by applicant]
European Search Report and Written Opinion for EP 08747813.7 received Jun. 22, 2010, 08 Pages.
[cited by applicant]
European Search Report and Written Opinion for EP 09723906.5 received Jun. 3, 2013, 5 Pages.
[cited by applicant]
European Search Report and Written Opinion for EP 09835809.6 received Nov. 13, 2012, 8 Pages.
[cited by applicant]
European Search Report and Written Opinion for EP 11835002.4 received Jul. 7, 2015, 6 Pages.
[cited by applicant]
European Search Report and Written Opinion for EP 12801372.9 received Mar. 26, 2015, 09 Pages.
[cited by applicant]
European Search Report and Written Opinion for EP 18171484.1 received Oct. 30, 2018, 13 Pages.
[cited by applicant]
European Summons to Attend Oral Proceedings with Annex for EP 12801372.9 dated May 16, 2017, 8 Pages.
[cited by applicant]
Feen et al. “Status Epilepticus” 2008, Southern Medical Journal 101:400-406, [Filed as EX1106 in PR2019-00451].
[cited by applicant]
Fetih et al. “Improvement of Absorption Enhancing Effects of N-Dodecyl-Beta-D-Maltopyranoside by Its Colon-Specific Delivery Using Chitosan Capsules” 2005, International J. Pharmaceutics 293:127-135.
[cited by applicant]
Fiest et al. “Prevalence and Incidence of Epilepsy, A Systematic Review and Meta-Analysis of International Studies” Jan. 17, 2017, Neurology 88:296-303, [filed as EX2005 in IPR2019-00451, IPR2019-00450, PR2019-00449].
[cited by applicant]
File History for EP 12801372.9, Based on WO2012/174158 and PCT/US2012/042311, filed Jan. 29, 2019 as EX1040 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 1—pp. 1-250.
[cited by applicant]
File History for EP 12801372.9, Based on WO2012/174158 and PCT/US2012/042311, filed Jan. 29, 2019 as EX1040 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 2—pp. 251-500.
[cited by applicant]
Ivaturi et al. “Bioavailability and Tolerability of Intranasal Diazepam in Healthy Adult Volunteers” Apr. 2009, Epilepsy Research 84(2-3): 120-126.
[cited by applicant]
Affidavit of Robert Cleary executed Nov. 21, 2019 [filed as EX2025 in IPR2019-00451].
[cited by applicant]
Affidavit of Ronald Figueroa executed Nov. 21, 2019 [filed as EX2026 in IPR2019-00451].
[cited by applicant]
Agarwal et al. “A Pilot Study Assessing the Bioavailability and Pharmacokinetis of Diazepam after Intranasal and Intravenous Administration in Healthy Volunteers” 2013, Epilepsy Research 105:362-367.
[cited by applicant]
Ahmad et al. “Efficacy and Safety of Intranasal Lorazepam Versus Intramuscular Paraldehyde for Protracted Convulsions in Children: an Open Randomised Trial” May 13, 2006, Lancet 367:1591-1597, [filed as EX1144 in IPR201…
[cited by applicant]
Ahsan et al. “Sucrose Cocoate, a Component of Cosmetic Preparations, Enhances Nasal and Ocular Peptide Absorption” 2003, International J. Pharmaceutics 251(1-2):195-203.
[cited by applicant]
Ahsan F., et al., “Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-β-cyclodextrin, on insulin movement across human bronchial epithelial cells,” European Journal of Pharmaceutical Sciences, 2003,…
[cited by applicant]
Albert et al. “Pharmacokinetics of Diphenhydramine in Man” 1975, J. Pharmacokinetics and Biopharmaceutics, 3(3):159-170.
[cited by applicant]
Appellant Neurelis Inc.'s Opening Brief filed Feb. 2, 2021 in Appeal Case No. 21-1038, Court of Appeals for the Federal Circuit, 184 Pages.
[cited by applicant]
Appellant Neurelis Inc.'s Reply Brief filed May 3, 2021 in Appeal Case No. 21-1038 (Court of Appeals for the Federal Circuit), 25 Pages.
[cited by applicant]
Arnold et al. “Correlation of Tetradecylmaltoside Induced Increases In Nasal Peptide Drug Delivery With Morphological Changes In Nasal Epithelial Cells” Sep. 2004, Journal of Pharmacy and Pharmaceutical Sciences 93(9):2…
[cited by applicant]
Assignment of U.S. Appl. No. 12/116,842 recorded at Reel: 027955 Frame: 0600, on Mar. 29, 2012, 3 Pages, [filed Jan. 29, 2019 as EX1049 in IPR2019-00451].
[cited by applicant]
Assignment of U.S. Appl. No. 12/933,701 recorded at Reel: 025034 Frame: 0531, on Sep. 23, 2010, 5 Pages, [filed as EX1047 in IPR2019-00451, IPR2019-00450, IPR2019-00449].
[cited by applicant]
Australia First Examination Report of Australia Patent Application No. 2009228093, dated Jul. 19, 2013, 02 pages.
[cited by applicant]
Beam et al. “Blood, Brain, Cerebrospinal Fluid Concentrations of Several Antibiotics in Rabbits with Intact and Inflamed Meninges” Dec. 1977, Antimicrobial Agents and Chemotherapy 12(6):710-716.
[cited by applicant]
Bechgaard et al. “Solubilization of Various Benzodiazepines for Intranasal Administration, a Pilot Study” 1997, Pharmaceutical Development and Technology 2:293-296, [Filed as EX2007 in IPR2019-00451].
[cited by applicant]
Behl et al. “Effects of Physicochemical Properties and Other Factors on Systemic Nasal Drug Delivery” 1998, Advanced Drug Delivery Reviews 29: 89-116, [Filed as EX1039 in IPR2019-00451, IPR2019-00450, IPR2019-00449].
[cited by applicant]
Berrocoso et al. “Opiates as Antidepressants” 2009, Current Pharmaceutical Design 15:1612-1622.
[cited by applicant]
Bhairi “A Guide to the Properties and Uses of Detergents in Biological Systems” 2001, Calbiochem, 1-42.
[cited by applicant]
Bhattacharyya et al. “Intranasal Midazolam vs Rectal Diazepam in Acute Childhood Seizures” 2006, Pediatric Neurologies 34:355-359, [filed as EX1140 in IPR2019-00451].
[cited by applicant]
Birkett et al. “Bioavailability and First Pass Clearance” 1991, Australian Prescriber 14:14-16.
[cited by applicant]
Birkett et al. “How Drugs are Cleared by the Liver” 1990, Australian Prescriber 13(4):88-89.
[cited by applicant]
Brown “Affinity Purification of a Somatostatin Receptor-G-Protein Complex Demonstrates Specificity in Receptor-G-Protein Coupling” Mar. 25, 1993, J. Biological Chemistry 268(9):6668-6676.
[cited by applicant]
Budavari et al. “The Merck Index” 1996, Editors, 12th Edition 14 Pages [filed as EX1076 in IPR2019-00451].
[cited by applicant]
Burstein et al. “Pharmacokinetics and Pharmacodynamics of Midazolam after Intranasal Administration” 1997, J. Clinical Pharmacology 37:711-718, [filed as EX1129 in IPR2019-00451].
[cited by applicant]
Canada Office Action in Canadian Application No. 2723470, mailed Feb. 19, 2015, 5 Pages.
[cited by applicant]
Canada Office Action in Canadian Application No. 2723470, mailed Jun. 7, 2012, 3 Pages.
[cited by applicant]
Canada Office Action in Canadian Application No. 2756690, mailed Feb. 19, 2015, 05 pages.
[cited by applicant]
Canada Office Action in Canadian Application No. 2756690, mailed Oct. 20, 2015, 03 pages.
[cited by applicant]
Castro et al. “Ecologically Safe Alkyl Glucoside-Based Gemini Surfactants” 2005, Issue in Honor of Prof Rosa LederKremer, Arkivoc, xii 253-267, ISSN 1424-6376.
[cited by applicant]
Cder Sep. 19, 2019—Abbreviated Approval Products: 505{b){2) or Anda, 2019, Retrieved from URL: https://www.jda.gov/drugs/cder-small-business-industry-assistance-sbia/abbreviated-approval-pathways-drug-product-505b2-or-a…
[cited by applicant]
Chavanpatil et al. “Nasal Drug Delivery of Sumatriptan Succinate” May 2005, Pharmazie 60(5):347-349.
[cited by applicant]
Chen et al. “Peptide Drug Permeation Enhancement by Select Classes of Lipids” Dec. 10-14, 2005, Presented at the 45th American Society of Cell Biology, S.F., CA, 01 Page.
[cited by applicant]
Chen-Quay et al. “Identification of Tight Junction Modulating Lipids” Feb. 2009, J. Pharmaceutical Sciences 98(2):606-619, retrieved from the internet: www.interscience.wiley.com (Jun. 18, 2008).
[cited by applicant]
Chien et al. “Nasal Systemic Drug Delivery” 1989, Anatomy and Physiology of the Nose, Drugs and the Pharmaceutical Sciences, Marcel Decker Chapter 1 39:29 Pages, [filed as EX1082 in IPR2019-00451].
[cited by applicant]
Chinese Office Action for application No. CN 200980157305.0, dated Jan. 28, 2013.
[cited by applicant]
Chinese Office Action for Chinese Application No. 201280039077.9, dated Aug. 11, 2015, 10 Pages.
[cited by applicant]
Chinese Office Action for Chinese Application No. 201280039077.9, dated Mar. 17, 2016, 6 Pages.
[cited by applicant]
Chinese Office Action for Chinese Application No. 201280039077.9, dated Nov. 21, 2016, 05 pages.
[cited by applicant]
Chinese Office Action for Chinese Application No. 201280039077.9, dated Dec. 26, 2014, 11 pages, [With English Translation].
[cited by applicant]
Chinese Office Action for Chinese Application No. 201710940124.1 dated Nov. 25, 2019, 14 Pages.
[cited by applicant]
Chinese Office Action for Chinese Application No. 201710940124.1, dated Sep. 28, 2020, 10 Pages.
[cited by applicant]
Chinese Reexamination Notification for Chinese Application No. 201280039077.9, dated Jun. 29, 2017, 5 Pages.
[cited by applicant]
Chiou et al. “Improvement of Systemic Absorption of Insulin Through Eyes with Absorption Enhancers” Oct. 1989, J. Pharmaceutical Sciences 78(10):815-818.
[cited by applicant]
Chiou et al. “Systemic Delivery of Insulin Through Eyes to Lower the Glucose Concentration” 1989, J. Ocular Pharmacology 5(1):81-91.
[cited by applicant]
Christensen et al. “Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide” 2010, Current Diabetes Reports 10(2):124-132.
[cited by applicant]
Cole et al. “Community Survey of Carers: Individual Epilepsy Guidelines (IEG) for Rescue Medication” 2009, Seizure 18:220-224, [filed as EX2015 in IPR2019-00451].
[cited by applicant]
Colombo et al. “Mucosal Drug Delivery, Nasal” Encyclopedia of Controlled Drug Delivery (Mathiowitz, editor), John Wiley & Sons, vol. 2 (1999): 592-605 [filed as EX1037 in IPR2019-00451, IPR2019-00450, IPR2019-00449].
[cited by applicant]
Complaint filed May 8, 2024 in U.S. District Court of Delaware,
[cited by applicant]
Corbo et al. “Measurement of Nasal Mucociliary Clearance” 1989, Archives of Disease in Childhood 64:546-550 (filed as EX2020 in IPR2019-00451).
[cited by applicant]
Corrected Brief for Appellee Aquestive Therapeutics, Inc., filed Mar. 31, 2021, in Appeal Case No. 21-1038, Court of Appeals for the Federal Circuit, 81 Pages.
[cited by applicant]
Transcript of Dr. Gizurarson's Deposition on Jan. 14, 2020, [filed as EX1149 in IPR2019-00451], 162 Pages.
[cited by applicant]
Transcript of Telephone Conference on Feb. 11, 2020, [filed as EX2027 in IPR2019-00451], 25 Pages.
[cited by applicant]
Tsuchido et al. “Lysis of Bacillus Subtilis Cells by Glycerol and Sucrose Esters of Fatty Acids,” Mar. 1987, Applied and Environmental Microbiology 53(3):505-508.
[cited by applicant]
Turker et al. “Nasal Route and Drug Delivery Systems” 2004, Pharmacy World and Science 26(3):137-142.
[cited by applicant]
Turton et al. “A Role for Glucagon-Like Peptide-1 in the Central Regulation of Feeding” Jan. 4, 1996, Nature 379:69-72.
[cited by applicant]
“UCB announces Nayzilam (Midazolam) Nasal Spray Now Approved by FDA to Treat Intermittent, Stereotypic Episodes of Frequent Seizure Activity in People Living With Epilepsy in the U.S” May 20, 2019, UCB Press Release, 14…
[cited by applicant]
U.S. Appl. No. 14/990,645, filed Jan. 7, 2016, 83 Pages.
[cited by applicant]
U.S. Appl. No. 60/148,464, filed Aug. 12, 1999, 93 Pages.
[cited by applicant]
U.S. Appl. No. 60/632,038, filed Nov. 30, 2004, 37 Pages, [filed as EX1065 in IPR2019-00451, IPR2019-00450].
[cited by applicant]
U.S. Appl. No. 61/040,281, filed Mar. 28, 2008, 25 Pages, [filed as EX1046 in IPR2019-00451, IPR2019-00450, IPR2019-00449].
[cited by applicant]
U.S. Appl. No. 61/040,558, filed Mar. 28, 2008, [filed as EX1008 in IPR2019-00451, IPR2019-00450, IPR2019-00449], 60 Pages.
[cited by applicant]
U.S. Appl. No. 61/497,017, filed Jun. 14, 2011, [filed as EX1005 in IPR2019-00451, IPR2019-00450, IPR2019-00449], 105 Pages.
[cited by applicant]
U.S. Appl. No. 61/570,110, filed Dec. 13, 2011, [filed as EX1006 in IPR2019-00451, IPR2019-00450, IPR2019-00449], 104 Pages.
[cited by applicant]
USP NF: “(1088) In Vitro and In Vivo Evaluation” 2003, The United States Pharmacopeia, The National Formulary, United States Pharmacopeial Convention Incoporated 2334-2339 Pages, [filed as EX1044 in IPR2019-00451, IPR20…
[cited by applicant]
USP NF: “The Official Compendia of Standards” 2003, Ethanol Alcohol 59-60, [filed as EX1078 in IPR2019-00451].
[cited by applicant]
“Valium: Brand of Diazepam Tablets” Jan. 2008, Label, Roche 12 Pages, [filed as EX1080 in IPR2019-00451].
[cited by applicant]
Van Der Lubben et al. “Chitosan and Its Derivatives in Mucosal Drug and Vaccine Delivery” 2001, European J. Pharmaceutical Sciences 14(3):201-207.
[cited by applicant]
Vidal et al. “Making Sense of Antisense” Nov. 9, 2005, European J. Cancer 41(18):2812-2818.
[cited by applicant]
Wang “Drug Delivery and Release System” Aug. 2007, China Medical Science and Technology Press 9 Pages.
[cited by applicant]
Wang et al. “Factors Predictive of Outcome in Posttraumatic Seizures” 2008, The J. Trauma 64(4):883-888, [filed as EX1103 in IPR2019-00451].
[cited by applicant]
Watanabe et al. “Antibacterial Carbohydrate Monoesters Suppressing Cell Growth of Streptoccus Mutans in the Presence of Sucrose” 2000, Current Microbiology 41:210-213.
[cited by applicant]
Weber et al. “Metabolism of Orally Administered Alkyl Beta-Glycosides in the Mouse” 1984, The J. Nutrition 114:247-254.
[cited by applicant]
Webpage for Anatrace Products of Affymetrix, retrieved from the internet: http://www.affymetrix.com/estore/browse/level_three_category_and_products.jsp?category=35843&categoryIdClicked=35843&expand=true&pare…
[cited by applicant]
Wermeling et al. “A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation,” Feb. 2009, Epilepsy Res. 83(2-3):124-132.
[cited by applicant]
Wermeling et al. “Bioavailability and Pharmacokinetics of Lorazepam after Intranasal, Intravenous, and Intramuscular Administration” 2001, J .Clinical Pharmacology 41:1225-1231, [filed as EX1134 in IPR2019-00451].
[cited by applicant]
Wermeling et al. “Pharmacokinetics and Pharmacodynamics of a New Intranasal Midazolam Formulation in Healthy Volunteers” 2006, Anesthesia & Analgesia 103(2):344-349, XP002585302.
[cited by applicant]
Wermeling “Intranasal Delivery of Antiepileptic Medications for Treatment of Seizures” Apr. 2009, Neurotherapeutics 6(2):352-358, [Filed as EX1151 in IPR2019-00451].
[cited by applicant]
Wikipedia “Benzodiazepine Overdose” Sep. 23, 2019, entire document, especially p. 2 paragraph 1, retrieved from the internet: https://en.wikipedia.org/w/index.php?title=Benzodiazepine_overdose&oldid=917464003 (Mar. …
[cited by applicant]
Cited By (1)